Customer Service: 866-788-9007
Vicki Fish-Sidlow Vice President, Skin Cancer Marketing Vicki Fish-Sidlow has served as our Vice President, Skin Cancer Marketing, since January 2022 and leads the development and execution of the marketing strategy for Castle’s dermatologic test portfolio. Ms. Fish-Sidlow is a dynamic, results-driven executive with more than 25 years of commercialization, management, strategy and leadership experience …
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Dec. 18, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL) today announced that the Company was recently added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to the market open on Monday, December 23, 2019. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market that are classified …
Castle Biosciences Added to NASDAQ Biotechnology Index Read More »
Data was presented during the 16th International Congress of the Society for Melanoma Research FRIENDSWOOD, Texas–(BUSINESS WIRE)–Nov. 25, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of data from an expanded, multi-center, prospectively tested patient cohort study supporting clinical use of the DecisionDx®-Melanoma test to …
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Nov. 20, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, will present at the following upcoming investor conferences: Piper Jaffray 31st Annual Healthcare Conference, New York Presentation on Wednesday, December 4, 2019, at 2:30 p.m. EST Evercore ISI 2nd Annual HealthCONx …
Castle Biosciences to Present at Upcoming Investor Conferences Read More »
Q3 2019 DecisionDx-Melanoma test report volume increased 32% compared to Q3 2018 Q3 2019 recognized revenues increased to $14.8 million, up from $3.7 million in Q3 2018 Q3 2019 gross margin increased to 88%, up from 64% in Q3 2018 December 2019 salesforce expansion Presented clinical validation data for DecisionDx-SCC Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, …
Castle Biosciences Reports Third Quarter 2019 Results Read More »
Data presented at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting FRIENDSWOOD, Texas–(BUSINESS WIRE)–Oct. 31, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of results from a study validating a newly developed nomogram tool that combines information from the DecisionDx®-Melanoma test …
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Oct. 29, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of a development update and validation data for its cutaneous squamous cell carcinoma (SCC) prognostic test, DecisionDx®-SCC. The study titled, “Development and validation of a prognostic gene expression profile …
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Oct. 28, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that it will release its financial results for the third quarter ended September 30, 2019, after the close of market on Monday, November 11, 2019. Company management will host a conference call and …
